NO20030925D0 - Gem-substituerte alfa V beta 3 integrinantagonister - Google Patents

Gem-substituerte alfa V beta 3 integrinantagonister

Info

Publication number
NO20030925D0
NO20030925D0 NO20030925A NO20030925A NO20030925D0 NO 20030925 D0 NO20030925 D0 NO 20030925D0 NO 20030925 A NO20030925 A NO 20030925A NO 20030925 A NO20030925 A NO 20030925A NO 20030925 D0 NO20030925 D0 NO 20030925D0
Authority
NO
Norway
Prior art keywords
gem
beta
integrin antagonists
substituted alpha
alpha
Prior art date
Application number
NO20030925A
Other languages
English (en)
Other versions
NO20030925L (no
Inventor
Ish Kumar Khanna
Yi Yu
Hwang Fun-Lu
Nizal Samuel Chandrakumar
Renee M Huff
Mark Andrew Russell
Mark L Boys
Lori Ann Schretzman
Barbara B Chen
Bipinchandra Nanubhai Desai
Srinivasan Raj Nagarajan
Alan Frank Gasiecki
Thomas D Penning
Thomas Rogers
John Adam Wendt
Albert Khilevich
Yaping Wang
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of NO20030925D0 publication Critical patent/NO20030925D0/no
Publication of NO20030925L publication Critical patent/NO20030925L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20030925A 2000-08-30 2003-02-27 Gem-substituerte <alfa>v<beta>3-integrinantagonister NO20030925L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22918600P 2000-08-30 2000-08-30
PCT/US2001/026963 WO2002018340A1 (en) 2000-08-30 2001-08-29 GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS

Publications (2)

Publication Number Publication Date
NO20030925D0 true NO20030925D0 (no) 2003-02-27
NO20030925L NO20030925L (no) 2003-04-24

Family

ID=22860154

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030925A NO20030925L (no) 2000-08-30 2003-02-27 Gem-substituerte <alfa>v<beta>3-integrinantagonister

Country Status (16)

Country Link
EP (1) EP1313705A1 (no)
JP (1) JP2004510708A (no)
KR (1) KR20030027106A (no)
CN (1) CN1471512A (no)
AU (1) AU2001288515A1 (no)
BR (1) BR0113671A (no)
CA (1) CA2419699A1 (no)
CZ (1) CZ2003459A3 (no)
EA (1) EA200300226A1 (no)
IL (1) IL154496A0 (no)
MX (1) MXPA03001759A (no)
NO (1) NO20030925L (no)
NZ (1) NZ524159A (no)
PL (1) PL365729A1 (no)
WO (1) WO2002018340A1 (no)
ZA (1) ZA200301162B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2528805A1 (en) * 2003-08-13 2005-05-06 Chiron Corporation Gsk-3 inhibitors and uses thereof
US20080064716A1 (en) * 2004-10-14 2008-03-13 Pharmacia Biphenyl Integrin Antagonists
CN101880270B (zh) * 2009-05-07 2012-10-03 上海华升生物科技有限公司 一种制备1,1-环丙烷二甲醇环亚硫酸酯的方法
JP6215335B2 (ja) 2013-09-24 2017-10-18 富士フイルム株式会社 新規な含窒素化合物もしくはその塩またはそれらと金属との錯体
UY38926A (es) * 2019-10-16 2021-05-31 Morphic Therapeutic Inc INHIBICIÓN DE INTEGRINA alfa4beta7 HUMANA

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
TR199801254T2 (xx) * 1995-12-29 1998-10-21 Smithkline Beecham Corporation Vitronektin resept�r� antagonistleri.
US5919792A (en) * 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
WO1999005107A1 (en) * 1997-07-25 1999-02-04 Smithkline Beecham Corporation Vitronectin receptor antagonist
HUP0003949A2 (hu) * 1997-09-24 2001-10-28 Smithkline Beecham Corp. Vitronektin receptor antagonisták, valamint a vegyületeket tartalmazó gyógyszerkészítmények

Also Published As

Publication number Publication date
AU2001288515A1 (en) 2002-03-13
NZ524159A (en) 2004-08-27
EP1313705A1 (en) 2003-05-28
WO2002018340A1 (en) 2002-03-07
ZA200301162B (en) 2004-05-12
CN1471512A (zh) 2004-01-28
NO20030925L (no) 2003-04-24
CZ2003459A3 (cs) 2003-09-17
CA2419699A1 (en) 2002-03-07
MXPA03001759A (es) 2004-11-01
EA200300226A1 (ru) 2003-10-30
PL365729A1 (en) 2005-01-10
IL154496A0 (en) 2003-09-17
KR20030027106A (ko) 2003-04-03
JP2004510708A (ja) 2004-04-08
BR0113671A (pt) 2004-01-06

Similar Documents

Publication Publication Date Title
DE69905248T2 (de) Neuropeptid y5-rezeptorantagonisten
NO20031268D0 (no) 4-aminokinazoliner
NO20032612D0 (no) CXCR3-antagonister
DE60136562D1 (de) Heteroaryl-harnstoff-neuropeptid-y-y5-rezeptor-antagonisten
EE200000171A (et) Uued NPY antagonistid
DE60030831D1 (de) Reissverschluss
DE69903961D1 (de) Muscarinagonisten und antagonisten
NO20004503L (no) Vitronectin-reseptor-antagonister
NO20000542L (no) Endothelin-antagonister
EE200000428A (et) VLA-4 antagonistid
NO20013013L (no) &lt;alfa&gt;v&lt;beta&gt;6-integrininhibitorer
NO20031267L (no) 4-aminokinazoliner
DE60009219D1 (de) Linearer Reissverschluss
NO20030925D0 (no) Gem-substituerte alfa V beta 3 integrinantagonister
NO20015237D0 (no) Integrinreseptor-antagonister
NO20016341D0 (no) Inhibitorer for integrinet &lt;alfa&gt;v&lt;beta&gt;6
NO20010620D0 (no) Vitronektinreseptor-antagonister
NO20020886D0 (no) Nye integrin- &lt;alfa&gt;v&lt;beta&gt;3-inhibitorer
NO20022158D0 (no) Rengjöringsblanding
ITAT990002U1 (it) Progetto &#34;millenium due&#34;
ITRC20000003U1 (it) &#34;bi ala - in&#34;
ITRC20000003A1 (it) &#34;bi ala - in&#34;
PT9613T (pt) Vysor 3 d
SE9900910D0 (sv) FreezeBox 2000
SE9901602D0 (sv) Jet-tröska 2000

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application